drugset / Trial / NCT03003468
Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017
Phase 1/2
Completed
35 enrolled
Lawrence Feldman, MD
HiberCell, Inc. · collabMerck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open label, multi-institutional, single arm study with a dose escalation phase Ib cohort, followed by a phase II cohort of pembrolizumab and Imprime PGG. No randomization or blinding is involved.
Timeline
- Start
- 2017-07-11
- Primary completion
- 2021-11-22
- Completion
- 2022-11-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imprime PGG | Other / unclassified | 2 mg/kg | Intravenous |
| Subject | Imprime PGG | Other / unclassified | 4 mg/kg | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |